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a  b  s  t  r  a  c  t
Clostridium difficile has emerged as an increasingly important nosocomial pathogen and the
prime causative agent of antibiotic-associated diarrhoea and pseudomembranous colitis in
humans. In addition to toxins A and B, immunological studies using antisera from patients
infected with C. difficile have shown that a number of other bacterial factors contribute to
the  pathogenesis, including surface proteins, which are responsible for adhesion, motil-
ity  and other interactions with the human host. In this study, various clostridial targets,
including FliC, FliD and cell wall protein 66, were expressed and purified. Phage antibody
display yielded a large panel of specific recombinant antibodies, which were expressed,
purified and characterised. Reactions of the recombinant antibodies with their targets were
detected by enzyme-linked immunosorbent assay; and Western blotting suggested that
linear rather than conformational epitopes were recognised. Binding of the recombinant
antibodies to surface-layer proteins and their components showed strain specificity, with
good  recognition of proteins from C. difficile 630. However, no reaction was observed for strain
R20291—a representative of the 027 ribotype. Binding of the recombinant antibodies to C.
difficile M120 extracts indicated that a component of a surface-layer protein of this strain
might possess immunoglobulin-binding activities. The recombinant antibodies against FliC
and  FliD proteins were able to inhibit bacterial motility.©  2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
iolog
years ago. It is the major cause of antibiotic-associated diar-Microb
Introduction
Phage display technology was first described by George
Smith,1 and since then it has emerged as an effective tool used
in various biological fields. One of the most important applica-
tions is selection of recombinant antibodies, independent of
the mammalian immune system. Based on the importance of
antibodies in medical research and therapy2–4 and the need
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to move away from hybridoma technologies,5,6 libraries of
recombinant molecules have emerged as key resources for
antibody discovery.7–9
The bacterial pathogen Clostridium difficile is an anaerobic,
Gram-positive, spore-forming organism, first discovered 80
10rhoeal disease and pseudomembranous colitis.11 Although
the large proteins, toxins A and B, are well-characterised vir-
ulence factors; other molecules are likely to contribute to the
iedade Brasileira de Microbiologia. This is an open access article
by-nc-nd/4.0/).
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recovered by selection. The remaining infected bacteria were
used for phage rescue by superinfection with 1010 plaque-
forming units (PFUs) of the KM13 helper phage. Phage particlesb r a z i l i a n j o u r n a l o f m i c 
isease process, notably those present on the bacterial sur-
ace. Cell surface proteins of C. difficile 630, such as Cwp66,12
wp8413 and SlpA,14 were analysed,15 and it has been shown
hat a significant number of them possess the cell wall-binding
fam04122 motifs. Other surface proteins, including flagellar16
nd GroEL-like proteins,17 which contribute to chaperone
unctions, may also directly or indirectly facilitate pathogen-
sis.
This study was aimed to isolate recombinant antibod-
es against certain surface proteins of C. difficile to facilitate
haracterisation of their location, function and contribution
o the pathogenesis. A phage display library of human-
sed single-chain variable-fragment antibodies (scFvs) was
creened against a range of recombinant clostridial proteins,
nd target-specific antibodies were characterised to elucidate
heir potential role in the biology of the pathogen.
aterials  and  methods
ulture  of  C.  difficile
hree strains of C. difficile (630, R20291 and M120) were
btained from a local culture collection. Autoclaved Brazier’s
CEY agar (Oxoid, Hampshire, UK) supplemented with 10 mL/L
f cycloserine/cefoxitin (250/8 mg/L) and 40 mL/L of egg yolk
as prepared for propagation of the organism. The bacterium
as grown for 48 h at 37 ◦C under anaerobic conditions. Brain
eart infusion (BHI) broth (20 mL)  was pre-incubated for 16 h
nder anaerobic conditions, then inoculated with a single
olony from an agar plate, and liquid cultures were grown
nder the above-mentioned conditions.
CR
mplification of candidate sequences was performed in 50 L
eactions, each containing 2 L of genomic DNA from C. diffi-
ile strain 630, 0.5 M each primer (Table 1), 200 M dNTPs and
.5 L of Phusion polymerase (New England Biolabs, Ipswich,
A,  USA). Thirty-five cycles of amplification were performed,
ach comprising denaturation at 94 ◦C (30 s), annealing at 55 ◦C
30 s) and extension at 72 ◦C (1 min). PCR products were char-
cterised by electrophoresis in a 1% agarose gel and purified
or cloning.
loning,  expression  and  purification  of  target  proteins
urified PCR products were cloned in the pET-32 Ek/LIC vector
ccording to the manufacturer’s instructions (Novagen, Madi-
on, WI,  USA). Aliquots (1 L) of the recombinant plasmid were
ransformed into thawed NovaBlue competent cells (50 L)
sing a brief heat shock at 40 ◦C. Transformants were selected
n L-agar containing ampicillin (50 g/mL), and then colony
CR and DNA sequencing were performed on the colonies
elected. Plasmid DNA was purified from 2-mL cultures of the
onfirmed transformants and transformed into Escherichia coli
L21(DE3) and BL21(DE3) pLysS cells. Then, 2 mL  of a 16-h
ulture of the bacterial strain was added to 200 mL  of 2×
T–ampicillin (50 g/mL) medium and grown to an absorbance
f 0.8 at 600 nm.  Isopropyl -d-1-thiogalactopyranoside (IPTG,o l o g y 4 7 (2 0 1 6) 394–402 395
1 mM final concentration) was then added and the cultures
were incubated for 16 h at 30 ◦C. Cells were collected from
the 16-h cultures by centrifugation at 3500 × g for 20 min  at
4 ◦C, then resuspended in PBS and disintegrated by ultrasoni-
cation. Following centrifugation under the above conditions,
recombinant histidine-tagged proteins were purified from
the supernatants by nickel-chelate affinity chromatography
on pre-packed 5-mL Hi-Trap columns (GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK). Proteins were eluted
with imidazole (100–500 mM), and fractions were analysed by
sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE), Western blotting and mass spectrometry.
Preparation  of  surface-layer  (S-layer)  extracts  using
low-pH  glycine  buffer
Cell wall proteins were extracted from cultures of the C. diffi-
cile strains (630, R20291 and M120) as described previously.15
Briefly, to extract S-layer proteins, bacterial pellets were resus-
pended in 0.04 M glycine (pH 2.2), and after 30-min incubation
at room temperature, intact cells were removed by centrifuga-
tion at 5000 × g for 10 min  at room temperature. Supernatants
containing the surface proteins extracted were neutralised to
pH 7.0 with 2 M Tris.
Expression  of  heat  shock  proteins
The C. difficile strains (630, R20291 and M120) were grown in
20 mL  of BHI liquid medium for 16 h under anaerobic condi-
tions and then heat-shocked under the same conditions at
42 ◦C for 2 h. Bacterial pellets were separated at 5000 × g for
10 min  at room temperature and stored at −20 ◦C.
Selection  of  scFv  antibodies  by  phage  display
Tomlinson libraries of humanised scFv antibodies (MRC Lab,
Cambridge, UK) were used for isolation of antibodies against
the recombinant clostridial target proteins. For selection,
immunotubes (Nunc, Pasadena, TX, USA) were coated with
a purified recombinant clostridial protein (4 mL at a concen-
tration of 100 g/mL in PBS). The tubes were washed three
times with PBS, then blocked with 2% skim milk–PBS, and
later 1013 phages from each library were added. After 2-h incu-
bation, the unbound viruses were washed out 10 times with
PBS containing 0.1% Tween 20, and the attached phages were
recovered by the addition of trypsin (0.5 mL,  1 mg/mL). Half
of the eluted phages were used to infect exponentially grow-
ing E. coli TG1. Serial dilutions of the infected bacteria were
plated on tryptone-yeast extract agar, containing 100 g/mL of
ampicillin and 1% glucose, to estimate the numbers of phageswere precipitated from 16-h culture supernatants with 20%
polyethylene glycol 6000–2.5 M NaCl, collected by centrifuga-
tion at 3300 × g for 15 min  and then titred on E. coli TG1 for the
next round of selection.
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Table 1 – List of sense and antisense primers, with the predicted size and molecular weight of the targets with and
without tag.
Target name
(CD)
Primers
Sense (upper sequence)
Antisense (lower sequence)
Predicted
product size
(BP)
Predicted
molecular
Mass of protein
(kDa)
Predicted
molecular mass
including tag
(kDa)
cwp84
(2787)
5′ GAC GAC GAC AAG ATA  GAT GGA GTA GAA ACT GCA GAG 3′
5′ GA GGA GAA GCC CGG TTC ATT TCC ATT TCC ACC AAC 3′
2265 82.04 102.51
cspA
(0892)
5′ GAC GAC GAC AAG ATG  AAA AAC GGA ATA GTA AAA TGG 3′
5′ GA GGA GAA GCC CGG TAC GTT TTC AGC TTG AGG TCC 3′
192 7.06 27.53
5′ cwp66
(2789)
5′ GAC GAC GAC AAG ATA  ACG GGT TCT GGA AGA TGG 3′
5′ GA GGA GAA GCC CGG TTT AGC TGC TAA TAC ACC CAC 3′
744 26.6 47.07
fbpA
(2592)
5′ GAC GAC GAC AAG ATA  CAT CAA CCT GAA GAT GAT GAG 3′
5′ GA GGA GAA GCC CGG TTT AAC CTT AAG CTT GGC TAC 3′
1689 64.71 85.18
groEL
(0194)
5′ GAC GAC GAC AAG ATTGGA GTA ACT ATA GCA AAA GAG 3′
5′ GA GGA GAA GCC CGG TCC GCC ACC CAT TCC TGG 3′
1461 51.73 72.2
fliD
(0237)
5′ GAC GAC GAC AAG ATT  CCA GTA AGA GTT ACA GGC 3′
5′ GA GGA GAA GCC CGG TTG TGA GAA ATA GTT CAT TTG 3′
1497 55.31 75.78
acd
(1304)
5′ GAC GAC GAC AAG ATT  GAA CCA ACT GCC GAA AGT AGC 3′
5′ GA GGA GAA GCC CGG TTC CAT AAT TCC AGA AAT TCC 3′
1650 59.75 80.22
fliC
(0239)
5′ GAC GAC GAC AAG ATG  GAG AAG TTA TCT TCT GGG 3′
5′ GA GGA GAA GCC CGG TAA AAC TCC TTG TGG TTG TTG 3′
780 27.57 48.04
3′ cwp66
(2789)
5′ GAC GAC GAC AAG ATA  GTT ACT CAA ATT GGT GGC 3′
5′ GAC GAC GAC AAG ATA  GTT ACT CAA ATT GGT GGC 3′
900 33.47 53.94
sortaseB
(2718)
5′ GAC GAC GAC AAG ATC  AAT CAT GAT ACT AAA ATA TCC 3′
5′ GA GGA GAA GCC CGG TCT ACCATGAATCAC C 3′
579 22.91 43.38
cwp66
(2789)
5′ GAC GAC GAC AAG ATA  ACG GGT TCT GGA AGA TGG 3′
5′ GAC GAC GAC AAG ATA  GTT ACT CAA ATT GGT GGC 3′
1722 62.75 83.22
ressio
specific primers (Table 1). The targets included Cwp84, Cwp66,The nucleotides shown in bold letters are required for LIC in the exp
Monoclonal  phage  enzyme-linked  immunosorbent  assay
(ELISA)
Individual colonies were selected from titration plates and
grown in 96-well plates to assess the specificity of the scFv
clones isolated by phage display. Each bacterial culture was
superinfected with 109 PFUs of the KM13 helper phage to pro-
duce clonal virus stocks. After overnight growth, the plates
were centrifuged at 1800 × g for 10 min, and the supernatants
were used in ELISA on plates pre-coated with relevant recom-
binant clostridial proteins. Phage binding was detected with
a monoclonal anti-M13 antibody conjugated to horseradish
peroxidise (Sigma, Dorset, UK).
Expression  and  purification  of  soluble  scFv  antibodies
Phages with properties of interest were used to infect non-
suppressor E. coli strain HB2151, which was plated on selective
agar containing 100 g/mL of ampicillin. The transfected
bacteria were then grown in a liquid medium to the late expo-
nential phase (absorbance of 0.9 at 600 nm)  before addition of
IPTG to a final concentration of 1 mM.  Growth was continued
for 16 h at 30 ◦C, and then the culture supernatants were used
in ELISA using a protein A–HRP conjugate to detect scFv bind-
ing to the relevant recombinant clostridial protein. The scFvs
were precipitated from the culture supernatants using ammo-
nium sulphate and dialysed against PBS, pH = 7. The dialysed
samples were purified by nickel affinity chromatography and
analysed by Western blotting using an anti-c-myc antibody
and an anti-rabbit-HRP conjugate (Sigma, Dorset, UK) to detect
the scFvs. Surface-layer protein A (SlpA) was extracted fromn vector.
C. difficile 630, separated by SDS–PAGE and then transferred to
a Hybond membrane. The membrane was probed with indi-
vidual scFvs to examine their binding by Western blotting.
Motility  inhibition  test
Bacterial motility inhibition assays were performed to evalu-
ate the properties of recombinant antibodies against flagellar
proteins. Cells of C. difficile strain 630 were serially diluted,
and 105 bacterial cells were incubated with 150 L of the puri-
fied scFvs against single protein components of the flagellar
structure, along with control reactions including M120 as a
non-motile strain. The mixtures were incubated for 1 h at 37 ◦C
under anaerobic conditions, and then one-tenth of the mix-
ture was deeply inoculated into 0.2% BHI agar. The cultures
were kept under the above-mentioned conditions and moni-
tored for growth over 48–72 h.
Results
PCR  of  clostridial  targets
Amplification of the genes for a number of clostridial proteins
with a putative surface location was optimised using gene-Acd, GroEL, FliD, FliC, CspA, FbpA and a putative sortase. The
amplicons were analysed by gel electrophoresis, their sizes
were confirmed as predicted from the genomic sequence of C.
difficile 630 (Fig. 1), and the DNA was isolated for cloning.
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Fig. 1 – Agarose gel electrophoresis of extracted PCR
products. Lane M,  1 kb DNA ladder; lane 1, cwp84 (predicted
size, 2265 bp); lane 2, cspA (189 bp); lane 3, 5′ region of
cwp66 (744 bp); lane 4, fbpA (1689 bp); lane 5, groEL (1461);
lane 6, fliD (1497 bp); lane 7, acd (1650 bp); lane 8, fliC
(780 bp); lane 9, 3′ region of cwp66 (900 bp); lane 10, sortaseB
(579 bp); lane 11, cwp66 (1722 bp). All PCR reactions were
carried out with Phusion DNA polymerase with buffer HF
(lanes 2, 3, 5, 6, 7, 8, 9, 10) or GC buffer (for lanes 1, 4 and
11).
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Fig. 2 – Western blot analysis of the extracts of E. coli BL21
(DE3) cells expressing the five target proteins. Lane M,
SeeBlue Plus2 pre-stained molecular weight markers
(Invitrogen); lane 1, Acd; lane 2, FliC; lane 3, C-terminus of
Cwp66; lane 4, SortaseB; lane 5, Cwp66. After transfer and
blocking, the recombinant proteins were detected with antiloning,  expression  and  purification  of  the  targets
olony PCR analysis using the target-specific primers showed
hat most of the transformants carried inserts of the size
xpected for each target, which were further confirmed by
equencing (S-tag or T7-specific primers, Novagen, Madison,
I,  USA). Except cwp84,  all the inserts were of the right length
nd in a correct frame with the fused tag used for detection
nd purification of the recombinant proteins. In the case of
wp84, original amplification appeared successful (Fig. 1, lane
); however, deletion most likely occurred during ligation or
ransformation. When the E. coli DE3 bacterial transformants
ere induced, Western blotting of the lysates showed success-
ul expression of most clostridial target proteins in the E. coli
ackground, and proteins of predicted molecular weights were
etected on the blots (Fig. 2). Peptidoglycan hydrolase Acd was
he only exception, for which no signal was detected (Fig. 2,
ane 1).
Most of the purified recombinant targets were identi-
al with the proteins of C. difficile 630, as confirmed by
DS–PAGE, mass spectrometry and Mascot analysis (data
ot shown). These proteins were sortase B, CspA, GroEL,
liC and FliD (flagellar components), N- and C-terminals of
wp66 along with the complete reading frame of Cwp66. A
ow-molecular-weight form of SlpA (designated LMW) and
 complete surface-layer structure comprised of high- and
ow-molecular-weight components (designated SlpA) were
btained from our collaborators. These materials were used as
argets in phage display to recover specific recombinant scFv
ntibodies.S-tag antibody, anti mouse-HRP and TMB  substrate.
Panning  and  selection  of  antibody  phages  from  scFv
libraries  I  and  J
Analysis performed during three rounds of selection revealed
increases in phage recovery rates. The monoclonal phage
ELISA assays demonstrated that 50–100% of all clones were
reactive against the intended target, although there was some
variation in the ELISA signal measured by absorbance at
450 nm (data not shown).
Expression  and  purification  of  soluble  scFvs  against
clostridial  targets
The scFvs producing the best signals in the ELISA assays
against the targets were scaled up using high-volume cultures.
Supernatants from the induced E. coli HB2151 transfectants
were purified by nickel affinity chromatography and using the
tag encoded by the display/expression vector, fused at the
termini of the recombinant antibodies. High yields of each
culture were obtained, and a series of 30-kDa proteins was
purified, predicted to be scFvs (Fig. 3). In general, the yields
were consistent, and 30-kDa proteins were observed in all
instances, despite the fact that one recombinant antibody
(anti-LMW scFv clone G7; lane 2) was present at high yield
and another was only weakly visible in the gel (anti-LMW scFv
clone A6; lane 4).
Sequence  analysis  of  scFvs
Approximately 600 clones with a high binding capacity to
the clostridial target proteins were identified, and of these
30 scFvs were chosen for sequence analysis. Plasmid DNAs
were purified and sequenced using primers for flanking vector
sequences and the primers that annealed to the linker coding
sequence separating the heavy- and light-chain domains of
each scFv. The results showed that the framework sequences
398  b r a z i l i a n j o u r n a l o f m i c r o
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Fig. 3 – SDS-PAGE analysis of scFvs against recombinant
LMW  (lanes 1–6) and extracted SlpA (lanes 7–9). Columns
were  loaded with the sample after adjusting pH and buffer
conditions and washed with binding buffer initially
without imidazole and then with buffer containing a low
concentration of imidazole (40 mM).  The scFv protein was
eluted with 200 mM imidazole in binding buffer. Lane M,
SeeBlue Plus2 Pre-Stained molecular weight markers
(Invitrogen); lane 1, anti-LMW clone F10; lane 2, G7; lane 3,
D4; lane 4, A6; lane 5, G1; lane 6, H1; lane 7, anti-SlpA clone
E10; lane 8, A10; lane 9, A9.
Table 2 – Amino acids present in CDR2 and CDR3 in heavy and 
position in the chains reading frame (e.g. “H50”, amino acid re
residue 50 in the scFv light chain; Kabat numbering system). Ro
sequence analysis. “G/E” designates a residue that could not be
CLONES H50 H52 H52a H53 H55 H56 H58 
CspA A9 T  E K Q E S D 
CspA E7 T  T T P A T T 
CspA G12 S S R T K G F 
N-terminus of Cwp66 A1 A G Y S S A R 
N-terminus of Cwp66 F4 T S R L T N L 
N-terminus of Cwp66 H2 S G Y S S A I 
C-terminus of Cwp66 A11 G N Y D Y T S 
C-terminus of Cwp66 B9 G T A N Y T S 
C-terminus of Cwp66 C9 R I P N Y T E 
Cwp66 A5 T S R L T N L 
Cwp66 C1 T S R L T N L 
Cwp66 F4 S S R L T N L 
GroEL E10 H T K E T G W 
FliC A4 G N S N Y T S 
FliC B5 G T A N Y T S 
FliC C9 R I P N T T E 
FliD B4 S T S T D Y G 
FliD F6 S A Y G D Y S 
SortaseB B8 T T S L D F S 
SortaseB D10 S T S L D F S 
SortaseB D11 S T S L D F Q 
LMW A6 S S G T Y S A 
LMW D4 S  S G T Y S A 
LMW F10 S Y A ? T R K 
LMW G1 T G T Y S S A 
LMW G7 G S T H S R Q 
LMW H1 T G T Y S S A 
SlpA A9 G S T H S R Q 
SlpA A10 T S T A K G H 
SlpA E10 L N A A T R L  b i o l o g y 4 7 (2 0 1 6) 394–402
were identical, as expected from the manner in which the
libraries were constructed. Amino acids present at diversi-
fied positions in the complementarity determining regions,
CDR2 and CDR3, of the heavy- and light-chains are assembled
for comparison in Table 2. In some cases, all scFv antibod-
ies against a particular clostridial target were unique, such
as clones A9, E7 and G12 directed against CspA (Table 2). The
diversified residues in these antibodies were all distinctive,
although E7 and G12 contained threonine or serine residues
in the heavy-chain domain with certain frequencies. In other
groups, near-identical sequences were recovered by screening
of the phage display libraries against a defined target. Similar
properties were also evident among the scFvs against Cwp66
and sortase B (Table 2). The six clones against LMW  were as
follows: A6 and D4 were identical, G1 and H1  formed a second
identical pair, whilst F10 and G7 were unique. The results of
restriction enzyme (NcoI and NotI) analysis conducted to eval-
uate the presence of full-length scFv reading frames showed
that all the scFvs were intact (Fig. 4).
Immunoblot  analysis  with  native  C.  difficile  proteinsAll purified scFvs were able to recognise the recombinant
clostridial targets used in selection by Western blots (data
not shown). Given that recombinant methods were used for
light chains of sequenced clones. Columns designate the
sidue 50 in the scFv heavy chain; “L50”, amino acid
ws  identify the clostridial target and the clone chosen for
 resolved from sequence traces.
H95 H96 H97 H98 L50 L53 L91 L92 L93 L94 L96
R K P P R H R M R A L
T R R M H R G T T L M
L S K R A S Q H R A H
N A Y T A Y S D N S A
N G A L A L S S V S P
N A Y T A Y S D N S A
Y S T S H G T A D S S
T G S N N S D G N S D
S G H T N I N S D A F
N G A L G S A W A L N
N G A L A L S S V S P
N G A L A L S S V S P
R R H H G Y F S R K S
Y G S N D N S N S Y S
S S T S N Y G N N N S
S G H T Q N P V S A P
T S S N G S D S N T A
S A Y N S A A S N T G
P A A T A S T T S T D
P A A T A S N L S T D
P S A T A S N T S T D
G D S F S T A S S S T
G D S F S T A S S S T
H P L I M M K K A T A
N A A A A S Y A Y Y T
N G T L Q E A Q S N Q
N A A A A S Y A Y Y T
N G T L Q E A Q S N Q
N Y P A P N H A T T P
S M R A K R G/E M S G T
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Fig. 4 – Restriction analysis for the presence of full-length
scFv inserts in clones from the Tomlinson library. Plasmid
DNA from each clone was digested with NcoI and NotI.
Release of a full-length scFv insert is expected to result in a
fragment of 717 bp. Lane M,  1 kb DNA ladder (Promega);
lane 1, FliD B4; lane 2, FliD B5; lane 3, FliD A6; lane 4, FliC
B5; lane 5, FliC F1; lane 6, LMW  F10; lane 7, LMW  H1; lane 8,
LMW  G7; lane 9, LMW  G1; lane 10, LMW  A6; lane 11, LMW
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Fig. 5 – Western blot analysis of the reaction of scFvs with
SlpA extracted from C. difficile 630. In each panel, the left
hand lane shows the migration of SeeBlue Plus2
pre-stained molecular weight markers (Invitrogen). Upper
panel: A, LMW  scFvs D4; B, H1; C, A6. Middle panel: D,4; lane 12, SlpA A10; lane 13, SlpA E10; lane 14, SlpA A9.
roduction of these proteins in E. coli,  analysis was carried out
o study the recognition of native forms of each protein.
All the anti-SlpA scFvs recognised the native target protein
rom C. difficile 630 on a Western blot; however, the patterns of
ecognition were sometimes unexpected. As shown in Fig. 5,
nti-LMW scFvs D4, H1, A6 (upper panel, A–C, respectively),
1 and F10 (middle panel, D and E, respectively) all recognised
he high-molecular-weight (HMW)  component of the native
lpA complex, despite having been isolated by selection on a
ecombinant form of the LMW  protein. The recognition was
trong, specific and unambiguous. In contrast, G7 (Fig. 5, mid-
le panel, F) isolated in the same selection experiment reacted
trongly with the LMW  protein. This result was also noticeable
n the reactions of SlpA A9 and SlpA E10; meanwhile, these
cFvs were isolated by selection on the native SlpA complex.
The scFvs against the SlpA protein of C. difficile 630 were
lso analysed on Western blots using extracts from C. difficile
30, R20291 and M120. None of the scFvs were able to bind
o the SlpA components of C. difficile R20291, but all showed
bility to attach to the SlpA components of strains 630 and
120 (data not shown). When analysing the extracts from C.
ifficile 630, R20291 and M120, reactions between the scFvs and
he putative native targets were generally obvious. However,
t was consistently observed, regardless of the selection or
pecificity, that the antibodies were bound to a protein from
120, which was of a similar molecular weight to that of
he LMW  component of SlpA (Fig. 6). In these experiments,
xtracts from C. difficile 630, M120 and R20291 were probed
ith three scFv clones against GroEL, of which only clone E10
ould react with its native target (58 kDa). However, a weak
ignal was also evident at a lower molecular weight in the
xtract from strain 630, and a much weaker signal was evident
n the extract from strain R202091, but the strongest signal
as detected at 36 kDa (Fig. 6, unshaded arrowhead). This sug-
ests a reaction between scFv E10 and the LMW  component of
lpA from the M120 strain. This finding was consistent when
xtracts of M120 were probed, irrespective of the specificity ofLMW  G1; E, F10; F, G7. Bottom panel: G, SlpA A9; H, E10.
the scFv and its reactivity with components in extracts from
M120 and the other strains, suggesting the presence of an
immunoglobulin-binding activity in extracts from C. difficile
strain M120.
Analysis  of  effects  of  scFvs  on  bacterial  motilityThe scFvs against the FliD (clone B5) and FliC (clone A6)
proteins were tested to assess whether their binding to the
bacterial surface would interfere with a specific biological
400  b r a z i l i a n j o u r n a l o f m i c r o
64 kDa
50
36
groEL 
LMW of slpA
Fig. 6 – Western blot analysis of reaction of scFv with GroEL
extracted from C. difficile 630, M120 and R20291. Heat
shocked bacterial lysate was prepared from the three
strains, separated by SDS-PAGE and transferred to Hybond
membrane that was then probed with anti-GroEL scFv
(from left E10, A1 and E9). Anti c-myc and anti-rabbit-HRP
conjugate were  used to detect the binding of scFv. The left
hand lane shows the migration of SeeBlue Plus2
pre-stained molecular weight standards (Invitrogen).
Moving to right, the lanes show extracts from C. difficile
630, M120 and R20291 respectively.activity such as motility (Fig. 7). In the images, bacterial mobil-
ity is apparent as diffuse growth from the stab inoculation
site. The three left images in the top row show the growth of
C. difficile 630 without an scFv (left) and pre-mixed with an
irrelevant scFv prior to inoculation (middle), as well as the
growth of the non-motile M120 strain without an scFv (right).
These images illustrate the diffuse pattern of growth of motile
bacteria. The three right images in the top row of Fig. 7 show
the growth of C. difficile 630 pre-incubated with undiluted (left),
10-fold diluted (middle) and 100-fold diluted (right) anti-FliC
scFv B5. The images in the bottom row of Fig. 7 show the results
obtained using the same experimental design with anti-FliD
Control 
FliD A6
Fig. 7 – Effect of recombinant antibodies on the motility of C. diffi
stabbed to agar and cultured for 48 h. Upper left pannel: C. difficil
(centre) and the non-motile strain M120 without scFv (right). Upp
scFv B5 (undiluted: left; 1/10: centre; 1/100: right). Bottom row: C.
(undiluted: left; 1/10: centre; 1/100: right). b i o l o g y 4 7 (2 0 1 6) 394–402
scFv A6. Although inhibition of bacterial motility by the anti-
FliC and anti-FliD scFvs could be seen under all conditions,
the range of inhibition gradually decreased with the increase
of the dilution factor.
Discussion
In many  intracellular and extracellular bacterial pathogens,
surface proteins play a crucial role in the pathogenesis.18,19
Synthesis of these proteins, their assembly on the surface,
activities and strain-to-strain differences are all promising
areas for exploitation in the development of therapeutics and
diagnostics. Analysis of the C. difficile proteome indicates that
approximately 50 surface components exist, many  being SlpA
paralogs and others having distinctive functions such as a role
in bacterial motility.
Phage display technology has provided a fast, efficient and
productive strategy for isolation of monoclonal antibodies and
allowed the screening and analysis of significant numbers of
clones. In this study, from the initial panel of 600 soluble anti-
bodies, 30 were chosen for the final panel of reagents. This is
the first report of the recombinant antibody selection against
a range of surface proteins of C. difficile.
Besides the unexpected interactions of selected anti-SlpA
630 antibodies with low- and high-molecular-weight compo-
nents, analysis of these binders against SlpA revealed that
the antibodies bind to extracts of the C. difficile 630 and M120
strains under both denaturing and non-denaturing condi-
tions; however, the scFvs failed to bind to extracts from the
R2029 strain. This suggests that the epitopes for this panel
of antibodies were probably linear, and hence treatment with
SDS did not disrupt the interaction sites. SlpA is a major
protein of C. difficile,20 comprised of two parts, of which the
HMW component may have a role in binding of the bac-
terium to host proteins, such as collagen. Accordingly, the
Fli C B5
cile. Bacteria were mixed  with scFvs, incubated, then
e 630 without scFv (left), scFv of irrelevant specificity
er right pannel: C. difficile 630 pre-incubated with anti-FliC
 difficile 630 pre-incubated with anti-FliD scFv A6
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otential exists for bacterial adhesion to be inhibited by spe-
ific immunological reagents.21 Regarding the anti-SlpA scFvs
solated in the current work, one future opportunity would
e to look for anti-HMW antibodies and test if they possess
imilar properties. One of the targets was GroEL as a heat
hock protein. Among all the scFvs selected against recombi-
ant clones of this protein, only clone E10 could react with
he native form. The results obtained with the extracts of
he C. difficile M120 strain showed that most of the scFvs
sed to probe Western blots appeared to be able to bind to
 protein of about 36 kDa, a size consistent with that of the
MW  component of SlpA from the M120 strain. Reactions with
omponents of this size were evident by analysing the scFvs
irected against GroEL, sortase B, FliC and CspA (data not
hown). Given the number of the scFvs that appeared to react
ith this protein, the most likely explanation is that it is able
o bind scFvs not through the interaction with residues in the
DRs of the antibodies, but via other parts of the recombinant
mmunoglobulin, similar to the cases of A and L proteins. It
as also been reported that some spore proteins of Bacillus
ubtilis are able to interact with scFvs, indicating that there
xist certain VH variants of the antibodies.22
The current study showed that binding of scFvs to the
liC and FliD targets could partially inhibit bacterial motil-
ty. Alignment of the FliC and FliD protein sequences from
wo strains (630 and 027) showed a high degree of identity
etween the two proteins, with greater variation in their cen-
ral regions. This alignment and the blotting results suggest
hat the binding site for the anti-FliC scFvs may lie in the vari-
ble central regions (data not shown). It has been reported
hat FliC from six strains reacted with a polyclonal anti-FliC
ntibody23; however, the molecular weight of the protein, pre-
icted from the gene sequence, was different from that of FliC
solated from the bacterial extracts. More  recent bioinformat-
cs analysis of different strains has shown that the protein
ndergoes glycosylation, and differences in the glycan biosyn-
hesis genes further affect the observed masses of FliC from
ifferent strains.24
In conclusion, this study validated a strategy for generat-
ng recombinant antibodies against selected targets from the
acterial pathogen C. difficile.  These reagents have a potential
n diagnostics, as well as for advancing understanding of the
isease process and developing new therapeutics.
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